100,000-Person study pits Weight-Loss drugs against heart attacks
NCT ID NCT07619508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two popular weight-loss medications, tirzepatide and semaglutide, in 100,000 adults who are overweight or obese and at risk for heart problems but do not have diabetes. Researchers are analyzing real-world data to see which drug better prevents death, heart attacks, or strokes. The goal is to guide doctors in choosing the best treatment for heart health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States